Abbott Laboratories vs Pfizer
ABT and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABT and PFE compare
Abbott Laboratories and Pfizer are about the same size, with market caps of $184B and $171B.
On earnings, Abbott Laboratories is cheaper: it trades at 34.1× trailing earnings, against 39.4× for Pfizer.
Abbott Laboratories grew revenue faster over the last twelve months (8.1% versus −0.21% for Pfizer).
Abbott Laboratories keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with 6.8% at Pfizer.
Both pay dividends: Abbott Laboratories yields 2.4% and Pfizer 5.7%.
Abbott Laboratories scores higher on the StockData Score (14 against 11 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABT | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $184B | $171B |
| Share price | $106.20 | $29.95 |
| Change, 1 year | −14.7% | 22.2% |
| Change, 5 years | −14.6% | −38.4% |
| Beta (5Y) | 0.47 | 0.44 |
| Employees | 115K | 75K |
| StockData Score | ||
| Total score | 14 (better) | 11 |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 34.1× (better) | 39.4× |
| P/S | 3.9× | 2.7× (better) |
| P/B | 3.6× | 2.0× (better) |
| EV/EBITDA | 28.8× | 16.7× (better) |
| P/FCF | 23.5× | 15.5× (better) |
| FCF yield | 4.3% | 6.4% (better) |
| Fair value | $78.11 | $19.52 |
| Margin of safety | −36.0% (better) | −53.4% |
| Growth | ||
| Revenue growth (TTM) | 8.1% (better) | −0.21% |
| Revenue growth, 5Y average | 5.1% | 8.5% (better) |
| Net income growth (TTM) | −61.2% | −59.7% (better) |
| EPS growth (TTM) | −61.1% | −59.6% (better) |
| EPS growth, 5Y average | 8.3% (better) | −3.6% |
| Profitability | ||
| Gross margin | 56.6% | 73.2% (better) |
| Operating margin | 15.8% | – |
| Net margin | 11.6% (better) | 6.8% |
| FCF margin | 16.8% | 17.2% (better) |
| Return on equity | 10.7% (better) | 5.0% |
| Return on invested capital | 7.9% | – |
| Financial health | ||
| Debt / equity | 0.64 (better) | 0.74 |
| Net debt / EBITDA | 3.68 (better) | 4.07 |
| Interest coverage | 9.6× | – |
| Current ratio | 1.38 (better) | 1.27 |
| Altman Z-score | 3.28 (better) | 2.03 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.4% | 5.7% (better) |
| Payout ratio | 78.5% | – |
| Years of dividend growth | 3 | 15 (better) |
| Dividend growth, 5Y average | – | 2.4% |
| Buyback yield | 1.00% | – |
| Shareholder yield | 3.4% | 5.7% (better) |
| Ownership | ||
| Held by institutions | 79.8% | 67.2% |
| Held by insiders | 0.50% | 0.03% |
| Insider net buying, 12 months | −$43.1M | $2.8M (better) |
| Superinvestors holding | 2 | 2 |
| Short interest, % of float | 0.79% | 2.6% |
Go deeper
- ABT stock overview
- ABT income statement
- ABT valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.